Materialise NV Announces Results of 2025 Extraordinary Shareholders’ Meeting

Materialise NV Announces Results of 2025 Extraordinary Shareholders' Meeting GlobeNewswire November 14, 2025 Leuven, Belgium, Nov. 14, 2025 (GLOBE NEWSWIRE) — Materialise NV (NASDAQ: MTLS), a leading provider of additive manufacturing software and of sophisticated 3D printing solutions, today announced the results of the votes cast at its Extraordinary Shareholders' Meeting, where all the proposed […]

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results GlobeNewswire November 14, 2025 – Company reports $14.3 million in revenue in Q3'25, consisting of $3.6 million in YCANTH(R) revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and alignment regarding the study design of a Phase 3 program

First Merchants Corporation Announces Cash Dividend

First Merchants Corporation Announces Cash Dividend GlobeNewswire November 14, 2025 MUNCIE, Ind., Nov. 14, 2025 (GLOBE NEWSWIRE) — First Merchants Corporation declared a cash dividend on November 14, 2025 of $0.36 per common share. The dividend is payable on December 19, 2025, to common shareholders of record as of December 5, 2025. About First Merchants

Capital Bancorp Appoints Jacob Dalaya as Chief Financial Officer

Capital Bancorp Appoints Jacob Dalaya as Chief Financial Officer GlobeNewswire November 14, 2025 ROCKVILLE, Md., Nov. 14, 2025 (GLOBE NEWSWIRE) — Capital Bancorp, Inc. (NASDAQ: CBNK) today announced the appointment of Jacob Dalaya as Executive Vice President and Chief Financial Officer of Capital Bancorp and Capital Bank, National Association, effective immediately. Prior to his appointment,

Dragonfly Energy Reports Third Quarter 2025 Results

Dragonfly Energy Reports Third Quarter 2025 Results GlobeNewswire November 14, 2025 Third Quarter Net Sales and Adjusted EBITDA Exceeded Guidance Driven by 44% OEM GrowthGross Margin Expanded 710 Basis Points Year-over-YearRecent Public Offerings and Debt Restructuring Significantly Improve Financial PositionGuides to Fourth Quarter Net Sales of Approximately $13.0 Million Third Quarter 2025 Financial Highlights (All

Biogen Completes Acquisition of Alcyone Therapeutics

Biogen Completes Acquisition of Alcyone Therapeutics GlobeNewswire November 14, 2025 CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery solutions, such as the ThecaFlex DRx(TM) drug delivery system. ThecaFlex DRx(TM) is an investigational implantable

Taitron Announces Voluntary Nasdaq Delisting, CFO Resignation and Third Quarter 2025 Results

Taitron Announces Voluntary Nasdaq Delisting, CFO Resignation and Third Quarter 2025 Results Notice of Plan to Voluntary Delist from Nasdaq and Deregister its Common Stock GlobeNewswire November 14, 2025 LOS ANGELES, Nov. 14, 2025 (GLOBE NEWSWIRE) — Taitron Components Incorporated (NASDAQ:TAIT) announces the Company will voluntarily delist its common stock from The Nasdaq Stock Market

Coherent Introduces Axon FP – A Breakthrough Fiber-Delivered Femtosecond Laser for Multiphoton Microscopy

Coherent Introduces Axon FP – A Breakthrough Fiber-Delivered Femtosecond Laser for Multiphoton Microscopy GlobeNewswire November 14, 2025 SAXONBURG, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: COHR), a global leader in photonics, today announced the launch of the Axon FP, a new addition to the Axon family that redefines flexibility and accessibility in

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire November 14, 2025 CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) — CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels

4DMT Announces New Employment Inducement Grants

4DMT Announces New Employment Inducement Grants GlobeNewswire November 14, 2025 EMERYVILLE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on November 11,

Scroll to Top